What are the best treatments for Pityriasis Rubra Pilaris?

Treatment for Pityriasis Rubra Pilaris (PRP) is highly individualized, typically focusing on systemic retinoids as the first-line therapy to manage skin cell turnover and inflammation. Because Pityriasis Rubra Pilaris is a chronic and unpredictable condition, management requires a multidisciplinary care team to address the physical, psychological, and dermatological impacts of the disease.

What are the first-line treatments for Pityriasis Rubra Pilaris?

There is no single "cure" for Pityriasis Rubra Pilaris, so treatment strategies prioritize symptom control and inducing remission. The current clinical standard involves oral retinoids, which are derivatives of Vitamin A. Acitretin (Soriatane) and isotretinoin (Accutane) are the most commonly prescribed systemic medications to help normalize skin keratinization. For patients who do not respond to retinoids, dermatologists may introduce phototherapy (specifically Narrowband UVB) or immunosuppressive agents like methotrexate to reduce systemic inflammation. Because the disease course varies, treatment effectiveness is highly subjective; what works for one patient may have limited utility for another.

What medications are commonly prescribed?

Managing the symptoms of Pityriasis Rubra Pilaris often involves a combination of systemic and topical therapies. While systemic medications address the underlying inflammatory process, topical agents are essential for maintaining skin barrier integrity. Common therapeutic options include:

• Systemic Retinoids: Acitretin and isotretinoin are the gold standard for reducing scaling and redness.


• Immunomodulators: Methotrexate, cyclosporine, or biologics (such as ustekinumab or secukinumab) may be considered in refractory cases.


• Topical Emollients: High-potency moisturizers, urea-based creams, and topical corticosteroids are used to manage localized scaling and relieve itching.


• Keratolytics: Preparations containing salicylic acid may help soften thickened skin on the palms and soles.

What is the role of a multidisciplinary care team?

Because Pityriasis Rubra Pilaris can significantly impact a patient’s quality of life and physical mobility, a coordinated care team is vital. A typical team includes a board-certified dermatologist as the lead physician. Depending on the patient's specific needs, the team may also include a rheumatologist (if joint involvement is suspected), a clinical psychologist to help navigate the emotional burden of chronic skin disease, and a geneticist if there is a concern regarding the rare familial form of the condition. At DiseaseMaps.org, we have observed that our 96 community members often find the most success when they take a proactive, collaborative approach with these specialists.

Are there emerging treatments for Pityriasis Rubra Pilaris?

Medical research is actively investigating the use of biologics for severe or treatment-resistant Pityriasis Rubra Pilaris. Recent clinical literature suggests that IL-17 and IL-23 inhibitors, which are often used for psoriasis, may show promise in managing the inflammatory pathways associated with this condition. However, these are typically considered "off-label" treatments, and patients should discuss the risks and benefits of participation in clinical trials with their medical team.

Next steps

• Consult with a board-certified dermatologist who has specific experience diagnosing and treating Pityriasis Rubra Pilaris.


• Keep a detailed symptom diary to track how different treatments affect your skin, which can help your doctor refine your personalized care plan.


• Connect with the 96 members of the DiseaseMaps.org community to share experiences and coping strategies.


• Ask your physician about potential clinical trials if standard systemic therapies are not providing adequate relief.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Pityriasis Rubra Pilaris overview.


• Orphanet: Rare disease database entry for Pityriasis Rubra Pilaris.


• PubMed Central (PMC): Recent clinical reviews on systemic retinoid efficacy in inflammatory dermatoses.


• Pityriasis Rubra Pilaris Support Group: Patient-centered resources and research updates.